HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $157
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Ligand Pharmaceuticals and raised the price target from $144 to $157, indicating a positive outlook for the company's stock.
October 21, 2024 | 9:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Ligand Pharmaceuticals and increased the price target from $144 to $157, suggesting a positive short-term outlook for the stock.
The analyst's decision to maintain a Buy rating and raise the price target indicates confidence in Ligand Pharmaceuticals' future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100